The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

Editorial summary Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Genome medicine Ročník 11; číslo 1; s. 43 - 3
Hlavní autori: Sabio, Erich, Chan, Timothy A.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 24.07.2019
BioMed Central Ltd
BMC
Predmet:
ISSN:1756-994X, 1756-994X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Editorial summary Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1756-994X
1756-994X
DOI:10.1186/s13073-019-0661-7